Biological Markers of Pathological Aging in Diseases of Men

Author Name(s): Kiryl I. Prashchayeu,Nina I. Zhernakova, ,Alexandr A. Pranovich, AndreyN.Ilnitskiy, Andrey A. Grishenko
Author Email: zhernakova@bsu.edu.ru

Abstract

This article searches for biological urogenital tract markers on the urothelium hyperfunction model in systemic atherosclerosis. We revealed the main parameters of pathological aging of urogenital tract. We have obtained the data that the pathological aging of urogenital tract is characterized by a significant increase in the acetylcholine expression from 0.52 to 0.82 cu, glutamate – from 0.53 to 0.83 cu, beta-1 transforming growth factor – from 0.452 to 0.497 ng/ml and a decrease in the levels of optical expression area in serotonin urothelium – from 0.43 to 0.36 cu and dopamine – from 0.42 to 0.35 cu. Within the framework of this article, we have proved that the indicators of urothelium expression of acetylcholine, glutamate, beta-1 transforming growth factor (an increase of their expression indicates pathological aging), the urothelium expression rates of serotonin and dopamine (a decrease in their expression indicates pathological aging) can be used as the biological markers of the pathological aging of urogenital tract on the combination model of urothelium hyperfunction and systemic atherosclerosis.

Introduction

In recent years, in connection with the development of a preventive trend in preventive gerontology, an increased attention is being paid to the search for pathological aging biological markers. And the development of preventive programs for men is of increasing interest [1, 2].

Such condition as a hyperactive bladder is the most significant gerontological problems in the incidence of men (GAB) [3]. The emergence of GAB is a big problem for men and leads to a decrease in social and physical activity with a decrease in productivity or a total refusal to work, forced restriction of sexual contacts, loss of self-esteem. The risk of developing a hyperactive bladder syndrome increases with age. The age of over 60 years old, where the GAB prevalence is maximal, is critical. An increase in the GAB risk for men is due not only to the age muscle disjunction, but also to the prostate hyperplasia, the signs of which are more or less present in about 50% of men aged 60 years old [4, 5, 6].

The role of concomitant diseases with a neurogenic and vascular component, such as diabetes mellitus, cerebrovascular pathology, atherosclerosis of large vessels, and others, which can cause or exacerbate detrusor contractility disorders, is undoubted for the GAB development in elderly patients. A special place is occupied by systemic atherosclerosis, diagnosed in 50-70% of cases of elderly people with GAB [7, 8, 9]. According to many sources, both GAB itself and GAB in combination with systemic atherosclerosis is pathology typical for men over 60 years old and is not an age norm and a characteristic of normal aging. That is why the presence of these conditions indicates the urogenital tract pathological aging [10, 11, 12].

Thus, in connection with the above, a high practical significance is the search for the pathological aging biological markers, as well as the opportunity to generalize and systematize the biological markers of urogenital tract pathological aging.

Summary

  1. The urogenital tract physiological aging is characterized by stable expression indices of beta-1 transforming growth factor in the lysate of uterine cells at an average level of 0.435 ng/ml, as well as the absence of statistically significant fluctuations in the optical density of expression of acetylcholine, glutamate, serotonin and dopamine in urothelium.
  2. The pathological aging of urogenital tract is characterized by a significant increase in the acetylcholine expression from 0.52 to 0.82 cu, glutamate – from 0.53 to 0.83 cu, beta-1 transforming growth factor – from 0.452 to 0.497 ng/ml and a decrease in the levels of optical expression area in serotonin urothelium – from 0.43 to 0.36 cu and dopamine – from 0.42 to 0.35 cu.
  3. The indicators of urothelium expression of acetylcholine, glutamate, beta-1 transforming growth factor (an increase of their expression indicates pathological aging), the urothelium expression rates of serotonin and dopamine (a decrease in their expression indicates pathological aging) can be used as the biological markers of the pathological aging of urogenital tract on the combination model of urothelium hyperfunction and systemic atherosclerosis.

References

[1] Apolikhin, O.I., Sevryukov F.A., KalininskayaA.A., Prostate Hyperplasia: Medical and Social Aspects, Modern Technologies of Surgical Treatment, 2012. Academy of Natural History: 115-134.

[2] Lebedev, V.V. Violations of Male Reproductive Health and Ways of their Prevention, 2012. Abstract: 15-24.

[3] Kulchavenya, E.V., BrizhatyukE.V., BreusovA.A. Hyperactive Bladder as a Mask of Chronic Prostatitis, 2012. Urology, 6: 43-47.

[4] Lesovoy, V.N., KolupaevS.M. Cytokines in the Hyperactive Bladder Pathogenesis, 2013. Scientific Bulletin of the Belgorod State University, 18: 37-39.

[5] Chernyshev, A.V. System and Quality of Medical Care for Patients with Male Reproductive Health Disorders and Possible Ways of Improvement, 2010. Bulletin of TSU, 2: 679-684.

[6] Chancellor, M.B.The overactive bladder progression to underactive bladder hypothesis, 2014. IntUrolNephrol, 46: 23-27.

[7] Schwarz, P.G., GoryachevF.K., PlotnikovA.N., SavvinD.Yu., Popov S.V. Differential Diagnosis and Treatment of Neurogenic and Psychogenic Urination Disorders Using the Example of Hyperactive Bladder Syndrome, 2013. Therapeutic Archive, 9: 86-92.

[8] Chuang, Y.C., Kaufmann J.H., Chancellor D.D., Chancellor M.B., KuoH.C.Bladder instillation of liposome encapsulated onabotulinumtoxinaimproves overactive bladder symptoms: a prospective, multicenter, double – blind, randomized trial, 2014. Journal Urology, 192(6): 1743-1749.

[9] Yamamichi, F., Shigemura K., Behnsawy H.M., Yamashita M., Shirakawa T., Fujisawa M. Beta-3 adrenergic receptors could be significant factors for overactive bladder-related symptoms, 2015. Int Journal ClinExpPathol., 8: 11863-11870.

[10] Gormley, E.A., LightnerD.J., Faraday M., VasavadaS.P. Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment, 2015. The Journal of Urology, 193 (5): 1572-1580.

[11] Nambiar, A., Lucas M. Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO), 2014. NeurourolUrodyn, 33: 21-25.

[12] Veit-Rubin, N., Meyer S., Achtari C.Overactive bladder syndrome-a public health challenge, 2016. Rev Med Suisse, 11: 492-495.

[13] WHO, 42nd session of the World Health Organization – World Health Assembly, 42nd session “Prevention and Control of Cardiovascular and other Chronic Noncommunicable Diseases” and the International Statistical Classification of Diseases and Related Health Problems, 2014. 10th revision.

791 total views, no views today

Download PDF File

About the author: admin